Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03739502 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant

Study acronym: HBO-UBC
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v9
  2. Primary completion date: Apr 2025 to Jun 2027
    • Study completion date: Apr 2026 to Jun 2027
    v8
  3. Re-verified, no change to tracked fieldsv7
  4. Primary completion date: Apr 2023 to Apr 2025
    • Study completion date: Apr 2023 to Apr 2026
    v6
  5. Primary completion date: Apr 2022 to Apr 2023
    • Study completion date: Jan 2023 to Apr 2023
    v5
Show 3 earlier versionsHide 3 earlier versions
  1. Primary completion date: Apr 2021 to Apr 2022
    • Study completion date: Jan 2022 to Jan 2023
    v4
  2. Re-verified, no change to tracked fieldsv3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Jan 2019 to Feb 28, 2019
    • Eligibility criteria expanded, about 70 words
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
University of Rochester
191 trials monitored
See 15 trials at risk
Leukemia
2,948 trials monitored
See 180 trials at risk
Non-Hodgkin Lymphoma
2,013 trials monitored
See 115 trials at risk
Acute Myeloid Leukemia (AML)
1,269 trials monitored
See 74 trials at risk
and 3 more diseases
The UCB transplant is a type of stem cell transplant used to treat cancer of the blood or lymph glands. The UCB transplant has advantages over other types of transplants such as ease of obtaining the umbilical cord blood, absence of donor risks, reduced risks of contagious infections, and the availability for immediate use. The UCB transplant is also associated with a lower incidence of graft versus host disease, or GvHD (in GvHD, the transplanted graft attacks the recipient organs).
Trial Details
NCT Number NCT03739502
Lead Sponsor University of Rochester
Conditions
(from sponsor)		 AML, NHL, Hodgkin Disease, All, Myelodysplastic Syndrome
Related terms Hodgkin Disease, Myelodysplastic Syndromes, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Enrollment 64 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov